Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
Tlemsani C, Huillard O, Arrondeau J, Boudou-Rouquette P, Cessot A, Blanchet B, Thomas-Schoemann A, Coriat R, Durand JP, Giroux J, Alexandre J, Goldwasser F. Tlemsani C, et al. Among authors: durand jp. Expert Opin Drug Metab Toxicol. 2015 May;11(5):785-94. doi: 10.1517/17425255.2015.1030392. Epub 2015 Mar 25. Expert Opin Drug Metab Toxicol. 2015. PMID: 25809423 Review.
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O, Boissier E, Blanchet B, Thomas-Schoemann A, Cessot A, Boudou-Rouquette P, Durand JP, Coriat R, Giroux J, Alexandre J, Vidal M, Goldwasser F. Huillard O, et al. Among authors: durand jp. Expert Opin Drug Saf. 2014 May;13(5):663-73. doi: 10.1517/14740338.2014.907270. Epub 2014 Apr 3. Expert Opin Drug Saf. 2014. PMID: 24693873 Review.
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.
Arrondeau J, Huillard O, Tlemsani C, Cessot A, Boudou-Rouquette P, Blanchet B, Thomas-Schoemann A, Vidal M, Tigaud JM, Durand JP, Alexandre J, Goldwasser F. Arrondeau J, et al. Among authors: durand jp. Expert Opin Investig Drugs. 2015 May;24(5):673-87. doi: 10.1517/13543784.2015.1005736. Epub 2015 Jan 20. Expert Opin Investig Drugs. 2015. PMID: 25599887 Review.
Sorafenib for patients with differentiated thyroid cancer.
Huillard O, Blanchet B, Durand JP, Goldwasser F. Huillard O, et al. Among authors: durand jp. Lancet. 2015 Jan 17;385(9964):227. doi: 10.1016/S0140-6736(15)60053-8. Lancet. 2015. PMID: 25706705 No abstract available.
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.
Tod M, Mir O, Bancelin N, Coriat R, Thomas-Schoemann A, Taieb F, Boudou-Rouquette P, Ropert S, Michels J, Abbas H, Durand JP, Dauphin A, Vidal M, Goldwasser F, Blanchet B. Tod M, et al. Among authors: durand jp. Pharm Res. 2011 Dec;28(12):3199-207. doi: 10.1007/s11095-011-0499-1. Epub 2011 Jun 21. Pharm Res. 2011. PMID: 21691893
Soluble VEGFR-1: a new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?).
Thomas-Schoemann A, Blanchet B, Boudou-Rouquette P, Golmard JL, Noé G, Chenevier-Gobeaux C, Lebbe C, Pages C, Durand JP, Alexandre J, Goldwasser F, Guibourdenche J, Vidal M. Thomas-Schoemann A, et al. Among authors: durand jp. J Clin Pharmacol. 2015 Apr;55(4):478-9. doi: 10.1002/jcph.429. Epub 2014 Dec 30. J Clin Pharmacol. 2015. PMID: 25401221 No abstract available.
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, Tod M, Loriot MA, Goldwasser F, Blanchet B. Boudou-Rouquette P, et al. Among authors: durand jp. PLoS One. 2012;7(8):e42875. doi: 10.1371/journal.pone.0042875. Epub 2012 Aug 13. PLoS One. 2012. PMID: 22912756 Free PMC article.
199 results